A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy
Lay Description
Category
- Urinary Tract and Kidney
- IRB Number
- 20220600HU
- NCT Number
- NCT # not yet entered
Eligibility
- Eligible Ages
- Eligible Genders
- Accepts Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Johnnie Jones
210-450-7277
jonesj21@uthscsa.edu
Lorannys Sanchez Tamarez
210-450-3937
sancheztamar@uthscsa.edu
Principal Investigator
Kumar Sharma